The gap between supply and demand in kidney transplantation has led to increased use of marginal kidneys; however, kidneys with acute kidney injury are often declined/discarded. To determine whether this policy is justified, we analyzed outcomes of donor kidneys with acute kidney injury (AKI) in a large UK cohort. A retrospective analysis of the UK Transplant Registry evaluated deceased donors between 2003 and 2013. Donors were classified as no AKI, or AKI stage 1-3 according to Acute Kidney Injury Network (AKIN) criteria. Relationship of AKI with delayed graft function/primary nonfunction (DGF/PNF), estimated glomerular filtration rate (eGFR), and graft-survival at 90 days and 1 year was analyzed. There were 11 219 kidneys (1869 [17%] with AKI) included. Graft failure at 1 year is greater for donors with AKI than for those without (graft survival 89% vs. 91%, p = 0.02; odds ratio (OR) 1.20 [95% confidence interval (CI): 1.03-1.41]). DGF rates increase with donor AKI stage (p < 0.005), and PNF rates are significantly higher for AKIN stage 3 kidneys (9% vs. 4%, p = 0.04) Analysis of association between AKI and recipient eGFR suggests a risk of inferior eGFR with AKI versus no AKI (p < 0.005; OR 1.25 [95% CI: 1.08-1.31]). We report a small reduction in 1-year graft-survival of kidneys from donors with AKI. We conclude that AKI stage 1 or 2 kidneys should be used; however, caution is advised for AKI stage 3 donors.
Introduction
There remains a wide gap between supply and demand in kidney transplantation. As of March 31, 2015, there were over 5000 patients on the transplant waiting list, with less than 3000 kidney transplants performed annually in the United Kingdom (1) . Kidney transplantation remains the treatment of choice for end-stage renal failure (ESRF), as it improves quality of life and reduces the mortality rate of patients with ESRF, compared to being on dialysis (2) . To bridge this gap between supply and demand, the donor pool has been expanded with the utilization of donors after circulatory death (DCD) and extended criteria donors (ECD). Results following DCD donation are comparable to those following DBD donation (3) . Transplantation with ECD donors has reduced graft survival versus standard criteria donors (SCD) (4-7), although this donor source still offers a survival benefit when compared to staying on dialysis or the waiting list (8, 9) .
Despite the persistent donor shortage, however, most transplant centers in many countries will decline donor kidneys with an acute kidney injury (AKI) at time of offering, due to a perception that this condition is not compatible with successful transplantation. This uncertainty leads to the frequent discard of many potentially viable donor kidneys (10) . In the United Kingdom, donation after brain death (DBD) kidneys are offered via a National Allocation System and DCD kidneys from donors younger than 50 years of age are offered regionally with one kidney being offered locally, and if the donor is over 50 years old both kidneys are offered locally (11) . This allocation policy is not altered when ECD kidneys, or kidneys with AKI are offered.
ischemic or toxic insult (13) , and the majority of patients with AKI may fully recover their renal function (14, 15) . Therefore, the use of kidneys from donors with an AKI could be considered to help reduce unnecessary discard and expand the donor pool.
To date, several classifications for AKI have been identified and validated. In 2004, the Acute Dialysis Quality Initiative (ADQI) group developed the "RIFLE" criteria, referring to Risk, Injury and Failure with the two outcome classes, Loss and End-Stage Renal Disease (16) . In 2007, a multidisciplinary collaborative network, the Acute Kidney Injury Network (AKIN), endorsed the RIFLE criteria with a small modification to include small changes in serum creatinine (≥0.3 mg/dL or ≥26.4 lmol/L) when they occur within a 48-h period (Table 1 ) (12) , and this classification was confirmed in 2011 by Kidney Disease: Improving Global Outcomes in its Clinical Practice Guideline for AKI (17) .
As it has been suggested that kidneys from donors with AKI may recover, it raises the question of whether discard of these kidneys is justified against the background of the persistent organ shortage. In this study we have investigated the effect of donor AKI on outcomes following kidney transplantation in a large UK cohort using the robust NHS Blood and Transplant UK Transplant Registry.
Patients and Methods
The study population consisted of all UK adult deceased donors where at least one kidney was offered for transplantation between January 1, 2003 and December 31, 2013. Change in serum creatinine between admission and retrieval, and urine output were used to classify each donor as AKI stage 1, 2, or 3 (17) . Donors who did not meet the AKIN criteria were classified as "no AKI." Donors without sufficient data to allow classification were excluded from all analyses. Offered kidneys used in first adult kidney-only transplants were included in posttransplant analyses.
Posttransplant endpoints
Transplant survival at 90 days and 1 year was used to measure shortand long-term outcome. This was defined as time from transplant to graft failure or patient death, censoring for patients who were alive with a functioning graft at the endpoint of the analysis.
Initial graft function was categorized as immediate function, delayed graft function (DGF), or primary nonfunction (PNF). DGF was defined as at least one dialysis treatment required in the first week after transplantation. Kidney function posttransplantation was measured using four categories of estimated glomerular filtration rate (eGFR) (≥60, 45-60, 30-45, and <30 mL/min/1.73 m 2 ). This was calculated using the fourvariable MDRD equation from serum creatinine values reported at approximately 90 days and 1-year posttransplantation. In order to reduce bias in the distribution of eGFR posttransplant, recipients whose graft had failed by each endpoint were included in an additional category: "returned to dialysis." Analyses were undertaken using SAS/STAT, version 9.4 (SAS Institute Inc., Cary, NC). There was no evidence that the relationship between each donor characteristic and AKI was different for each offering outcome, except for donor type. Of donors whose kidneys were offered but not accepted, DBD donors are more likely to be classified as AKI than DCD donors, whereas of donors whose kidneys were transplanted, DCD donors are more likely to be classified as AKI than DBD donors.
Statistical analysis
Offering outcomes Overall, 16 735 (72%) of 23 204 offered kidneys from the 11 649 donors were transplanted and 6469 (28%) kidneys from 3563 donors were not used ( Figure 1 ). For all 11 649 donors, where both kidneys were offered, the offering outcome was different for each kidney in the pair in 653 (6%) of cases. In the majority (631, 97%) of these 653 cases, at least one kidney was transplanted. The proportion of kidneys not used due to poor function was significantly different for donors at the different AKI stages, and this association was different at each stage of offer (p < 0.005) ( (4) 69 (4) 19 (4) 13 (2) 7 (2) 5 (4) 1108 (13) 872 (13) 177 (13) [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] 170 (7) 118 (7) 35 (7) 35 (6) 25 (6) 8 (6) 1178 (14) 958 (14) 169 (12) 40-49 345 (15) 229 (14) 91 (18) 81 (14) 58 (15) 14 (10) Table 4 . We found no difference in recipient groups with and without AKI with respect to age (p = 0.39), time on the transplant list (p = 0.14), primary renal disease (p = 0.72), ethnicity (p = 0.34), and sensitization (p = 0.12), although level of HLA mismatch was higher for recipients of AKI donor transplants (p < 0.005).
Of these 12 308 transplants, 1064 (8.6%) were excluded from further analyses due to missing data, 25 (0.2%) due to inadequate follow-up data. Therefore, 11 219 transplants were considered for inclusion in the analyses of posttransplant outcome and kidney function. Eight hundred ninety-seven (8%) had no initial graft function data and were excluded from the DGF/PNF analysis and 985 and 692 had no serum creatinine reported at 90 days and 1 year posttransplant and were excluded from kidney function analyses.
Transplant survival
Kaplan-Meier estimates of transplant survival after first adult kidney-only transplant by donor AKI stage suggests some evidence that the chance of graft failure/recipient death after first adult kidney-only transplant differs across AKI stage (p = 0.05) (data not shown). Due to the small numbers of events (<30) for some AKI stages, we then compared donors with and without AKI, which found that the chance of graft failure/recipient death after first adult kidney-only transplant is greater for donors with AKI than for those with no AKI (p = 0.02) (Figure 2 ).
After risk adjustment, there was no evidence of an association between transplant survival and donor AKI within 90 days posttransplant (p = 0.24), but there was an association within 1 year posttransplant (p = 0.02) ( 
Initial graft function
Risk of DGF and PNF increase with donor AKI stage (p < 0.005 and 0.04, respectively) ( Table 6 ). Odds of DGF are similar whether the donor is classified as AKI stage 1 
Discussion
The aim of this analysis was to assess the impact of donor AKI, as classified by the AKIN criteria, on outcomes in kidney transplantation. The question was whether discard of scarce donor kidneys is justified, if kidneys from donors with AKI are likely to result in a high percentage of graft failure and need for retransplantation. We have found that 17% of potential kidney donors have AKI (9% AKIN stage 1, 5% AKIN stage 2, and 3% AKIN stage 3), and so could contribute significantly to the donor pool.
Despite the expanding discrepancy between the number of patients waiting for a kidney transplant and the number of kidney donors, 28% of kidneys in this study are not used. As expected, kidneys are more likely to be declined due to higher AKIN stage, and kidneys with AKI stage 3 are 20 times more likely to be discarded than those with no AKI.
However, this analysis has shown that 1-, 3-, and 5-year graft survival is only 2% lower when using kidneys from donors with AKI. Although this difference is statistically significant, we question whether this reduction in graft survival is clinically relevant. This reduced graft survival needs to be taken in the context of remaining on the transplant waiting list with an annual death rate of 8.2% 669 (7) 149 (8) 40-84 872 (9) 146 (7) ≥85 334 (3) 69 (4) Data are reported as N (%).AKI, acute kidney injury. (8). The 20% increased risk of graft failure due to AKI in the donor is similar to the 17% increased risk of graft failure associated with dialysis vintage of 6 months when compared to pre-emptive transplantation, and is significantly lower than the 37% and 55% increased risk of graft failure when dialyzing for longer than 1 or 2 years prior to kidney transplantation (20) .
As would be expected, the rates of DGF increase as the AKI stage rises, and more importantly, the risk of PNF significantly increases when kidneys from donors with AKI stage 3 are transplanted (9% vs. 4% with no AKI). This is not necessarily an unexpected finding as Ali et al found that patients with severe AKI were less likely to recover their renal function (15) .
Although there is a risk of an inferior eGFR at 1 year when using kidneys with AKI, this absolute reduction is only 1.6 mL/min/1.73 m 2 and is unlikely to be of clinical significance.
To investigate whether there was a cumulative effect of AKI with many other risk factors known to be pertinent in kidney transplantation, we performed a Cox-regression analysis to examine the interaction of AKI with many of these risk factors, and surprisingly did not find any interactions. This was especially surprising for age, as previous studies have found that increasing age is a risk for the development of chronic kidney disease (CKD) in patients following AKI (21, 22) .
Our findings in the United Kingdom are consistent with Kayler's analysis of the Scientific Registry of Transplant Recipients in the United States between January 1995 and July 2007 (82 262 kidney transplant recipients). This study found that kidneys from SCDs with a terminal creatinine of over 2 mg/dL had a graft survival that is as good as those from donors with a terminal serum Hazard ratio reported for models where effect/interaction significantly associated with outcome. Interaction models also include main effects. All models adjusted for the following risk factors: Recipient-age, time on transplant list, primary renal disease, HLA mismatch, ethnicity, sensitization, CIT, DGF. Donor-age, type, BMI, sex, history of hypertension, length of stay in the hospital, use of adrenaline, ethnicity, blood group, cause of death. AKI, acute kidney injury; CI, confidence interval; CIT, cold ischemic time; DGF, delayed graft function; hx, history. creatinine of ≤1.5 mg/dL. If the donor was classed as an ECD, then the survival was worse if they had renal dysfunction, but equivalent to ECD donors with no AKI (23).
More recently, Hall, in New Haven, analyzed the outcomes of 886 kidneys with AKI, comparing them to 2378 kidneys without AKI, using the AKIN criteria to define the severity of AKI. This study found that rates of DGF increased as the AKI stage increased, as we have also shown, and this did not lead to worse survival, since there was no significant difference in 1-year graft survival between the groups (24) . In this analysis, the 6-month eGFR was no different between the groups, but the 1-year data were not complete, and so we are unable to compare with our findings. Heilman et al compared kidneys with no AKI to those with AKI, defined as a terminal creatinine of ≥2.0 mg/dL. They also used the AKIN criteria to define the severity of AKI. As their control group includes many AKIN stage 1 kidneys, it is difficult to draw comparisons between their findings and ours. They found no significant difference in 1-year graft survival between the AKI and control groups, and no difference in 1-year eGFR, which may be because the control group included kidneys that had a mild form of AKI (25) .
Transplantation continues to be the treatment of choice for patients with end-stage renal failure, and as an increasing number of patients are listed, the need to expand the donor pool has inevitably led to the acceptance of organs that are deemed to be "marginal." In many European national or international organ-sharing systems, it is current practice to not accept donor kidneys with AKI due to a perceived bad outcome after transplantation and need to return to dialysis. Our data demonstrate that these policies appear to be unjustified.
As pointed out in a recent review by a collaboration of attorneys and clinicians, the perceived risk should be discussed with the potential recipients of these organs so that they can make an informed decision (26) . Despite many achievements in transplantation, uncertainty whether to accept donor organs for a particular recipient persists. Thus, to support better clinical decision making but also to prevent unnecessary discard, more evidence is needed. In this study we have looked at the outcomes of a large cohort of marginal kidneys in the United Kingdom, in an attempt to give clinicians as much information as possible to make an . Odds ratio reported for models where effect/interaction significantly associated with outcome. Interaction models also include main effects. All models adjusted for the following risk factors: Recipient-age, time on transplant list, primary renal disease, HLA mismatch, ethnicity, sensitization, CIT, DGF. Donor-age, type, BMI, sex, history of hypertension, length of stay in hospital, use of adrenaline, ethnicity, blood group, cause of death. AKI, acute kidney injury; CI, confidence interval; CIT, cold ischemic time; DGF, delayed graft function; hx, history.
informed decision as to whether to use these kidneys, which they can then share with their patients to try to quantify this risk.
From these results, it would seem that in the United Kingdom, transplant clinicians are correctly identifying kidneys to be used for transplantation, and that we are appropriately cautious with kidneys with AKIN stage 3. This caution comes from evidence that as the severity of AKI increases, so does the risk of developing CKD (22, 27, 28) , with Chawla et al demonstrating that as the RIFLE score increased, the odds of developing CKD stage 4 increased significantly (22) . The hypothesis behind this could be that the tubular injury, inflammation, endothelial cell dysfunction, and vascular injury seen in AKI are exacerbated by the ischemia-reperfusion injury during transplantation, leading to renal fibrosis and impaired longer-term function (29, 30) .
This study has its limitations. As a retrospective registry review, there has already been a selection bias with clinicians selecting the donors that are perceived to be at lower risk. Although we can review the number of kidneys with AKI that were discarded and the reasons they were, we are unable to predict their outcome to see whether they were appropriately rejected. Unfortunately, we are unable to analyze whether the results seen are due to an effect of differences in immunosuppression, as the information about the immunosuppression used for each patient is poorly captured on the registry. Most UK centers will have individual immunosuppression protocols that will include a calcineurin inhibitor and an antiproliferative, and most centers will not alter this for kidneys with an AKI. We have adjusted our results according to center and we hope that this minimizes some of the uncertainty with this.
Other studies that have shown good outcomes with AKI kidneys, and have had a high proportion of kidneys with "severe" injury being preserved using hypothermic machine preservation (24) . Unfortunately, this is one area of the UK registry that is not well populated, and we were unable to examine whether the kidneys in this study were preserved in this manner. As machine preservation is becoming more frequently used, this could be an important novel technology to assess and condition injured kidneys, allowing them to be transplanted.
In conclusion, this large UK study has demonstrated that although a fair number of kidneys with AKI are still discarded, the ones that are actually transplanted give good outcomes. Over the 10-year period observed, in the United Kingdom over 1600 recipients received a kidney from a donor with AKI and still had a functioning graft at 1 year. We suggest that kidneys from donors with AKI stage 1 and 2 should not be discarded as they give comparable outcomes to kidneys from donors with no AKI. Discard of these viable donor kidneys is not justified, and transplantation will increase utilization in many countries, significantly reducing waiting lists once the current "decline policy" has been amended. Due to the size of the cohort in this study, we add that caution is advised for AKI stage 3 kidneys.
